Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Eleven analysts rate Harrow a "Moderate Buy" (8 buys, 2 holds, 1 sell) with an average 1‑year price target of $69.86 versus a recent open near $40.90, suggesting notable analyst-implied upside.
• Investor and financial snapshot: Institutional investors own about 72.76% of the stock with several funds recently increasing positions, while Harrow has a $1.52B market cap, a negative P/E (-240.57), a quick ratio of 2.06 and a high debt‑to‑equity ratio of 4.67.

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $69.8571.

Several equities research analysts have commented on the company. William Blair reissued an "outperform" rating on shares of Harrow in a report on Tuesday, March 3rd. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Harrow in a report on Thursday, March 19th. B. Riley Financial reaffirmed a "buy" rating and issued a $65.00 price target (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Zacks Research upgraded shares of Harrow from a "strong sell" rating to a "hold" rating in a research note on Friday, April 3rd. Finally, Weiss Ratings downgraded shares of Harrow from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, April 22nd.

Harrow Stock Performance

Harrow stock opened at $40.90 on Friday. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The company has a market capitalization of $1.52 billion, a P/E ratio of -240.57 and a beta of 0.34. The stock's 50 day moving average is $39.16 and its 200 day moving average is $42.41. Harrow has a twelve month low of $21.12 and a twelve month high of $54.85.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently made changes to their positions in HROW. Royal Bank of Canada grew its holdings in shares of Harrow by 102.5% during the first quarter. Royal Bank of Canada now owns 9,813 shares of the company's stock valued at $261,000 after buying an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock worth $483,000 after acquiring an additional 790 shares during the last quarter. Strs Ohio bought a new position in Harrow in the 1st quarter valued at approximately $149,000. Legal & General Group Plc lifted its position in Harrow by 12.4% in the 2nd quarter. Legal & General Group Plc now owns 30,753 shares of the company's stock valued at $939,000 after acquiring an additional 3,384 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Harrow by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company's stock valued at $1,434,000 after purchasing an additional 3,994 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.